PDLIM5 and prostate carcinoma: Genotyping chip detection experiments have shown that PDLIM5 is overexpressed in prostate cancer tissue (Koutros et al., 2013), and some studies have proved that the utility of serum and urine PDLIM5 levels as indicators for auxiliary diagnosis of prostate cancer, with potential value in predicting the risk of progression in advanced prostate cancer (PCA) (Ma et al., 2014).